These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
192 related articles for article (PubMed ID: 17314110)
1. Lipoprotein-associated phospholipase A2 does not predict mortality or new ischaemic events in acute coronary syndrome patients. Oldgren J; James SK; Siegbahn A; Wallentin L Eur Heart J; 2007 Mar; 28(6):699-704. PubMed ID: 17314110 [TBL] [Abstract][Full Text] [Related]
2. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study. Mohler ER; Ballantyne CM; Davidson MH; Hanefeld M; Ruilope LM; Johnson JL; Zalewski A; J Am Coll Cardiol; 2008 Apr; 51(17):1632-41. PubMed ID: 18436114 [TBL] [Abstract][Full Text] [Related]
3. The impact of circulating total homocysteine levels on long-term cardiovascular mortality in patients with acute coronary syndromes. Foussas SG; Zairis MN; Makrygiannis SS; Manousakis SJ; Patsourakos NG; Adamopoulou EN; Beldekos DJ; Melidonis AI; Handanis SM; Manolis AJ; Hatzisavvas JJ; Argyrakis SK Int J Cardiol; 2008 Mar; 124(3):312-8. PubMed ID: 17433477 [TBL] [Abstract][Full Text] [Related]
4. Lipoprotein-associated phospholipase A2: an independent predictor of coronary artery disease events in primary and secondary prevention. Anderson JL Am J Cardiol; 2008 Jun; 101(12A):23F-33F. PubMed ID: 18549868 [TBL] [Abstract][Full Text] [Related]
5. Prognostic utility of lipoprotein-associated phospholipase A2 for cardiovascular outcomes in patients with stable coronary artery disease. Sabatine MS; Morrow DA; O'Donoghue M; Jablonksi KA; Rice MM; Solomon S; Rosenberg Y; Domanski MJ; Hsia J; Arterioscler Thromb Vasc Biol; 2007 Nov; 27(11):2463-9. PubMed ID: 17766330 [TBL] [Abstract][Full Text] [Related]
6. Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker. Corson MA; Jones PH; Davidson MH Am J Cardiol; 2008 Jun; 101(12A):41F-50F. PubMed ID: 18549871 [TBL] [Abstract][Full Text] [Related]
7. Prognostic value of growth-differentiation factor-15 in patients with non-ST-elevation acute coronary syndrome. Wollert KC; Kempf T; Peter T; Olofsson S; James S; Johnston N; Lindahl B; Horn-Wichmann R; Brabant G; Simoons ML; Armstrong PW; Califf RM; Drexler H; Wallentin L Circulation; 2007 Feb; 115(8):962-71. PubMed ID: 17283261 [TBL] [Abstract][Full Text] [Related]
8. The role of lipoprotein-associated phospholipase A(2) in the metabolic syndrome and diabetes. Noto H; Chitkara P; Raskin P J Diabetes Complications; 2006; 20(6):343-8. PubMed ID: 17070436 [TBL] [Abstract][Full Text] [Related]
9. Effects of a low-calorie diet associated with weight loss on lipoprotein-associated phospholipase A2 (Lp-PLA2) activity in healthy obese women. Tzotzas T; Filippatos TD; Triantos A; Bruckert E; Tselepis AD; Kiortsis DN Nutr Metab Cardiovasc Dis; 2008 Sep; 18(7):477-82. PubMed ID: 17928209 [TBL] [Abstract][Full Text] [Related]
10. Troponin-T and N-terminal pro-B-type natriuretic peptide predict mortality benefit from coronary revascularization in acute coronary syndromes: a GUSTO-IV substudy. James SK; Lindbäck J; Tilly J; Siegbahn A; Venge P; Armstrong P; Califf R; Simoons ML; Wallentin L; Lindahl B J Am Coll Cardiol; 2006 Sep; 48(6):1146-54. PubMed ID: 16978997 [TBL] [Abstract][Full Text] [Related]
11. Metalloproteases 2 and 9, Lp-PLA(2) and lipoprotein profile in coronary patients. Muzzio ML; Miksztowicz V; Brites F; Aguilar D; Repetto EM; Wikinski R; Tavella M; Schreier L; Berg GA Arch Med Res; 2009 Jan; 40(1):48-53. PubMed ID: 19064127 [TBL] [Abstract][Full Text] [Related]
12. Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study. Kiechl S; Willeit J; Mayr M; Viehweider B; Oberhollenzer M; Kronenberg F; Wiedermann CJ; Oberthaler S; Xu Q; Witztum JL; Tsimikas S Arterioscler Thromb Vasc Biol; 2007 Aug; 27(8):1788-95. PubMed ID: 17541022 [TBL] [Abstract][Full Text] [Related]
17. Prognostic value of biomarkers during and after non-ST-segment elevation acute coronary syndrome. Eggers KM; Lagerqvist B; Venge P; Wallentin L; Lindahl B J Am Coll Cardiol; 2009 Jul; 54(4):357-64. PubMed ID: 19608034 [TBL] [Abstract][Full Text] [Related]
18. Urotensin-II levels in acute coronary syndromes. Joyal D; Huynh T; Aiyar N; Guida B; Douglas S; Giaid A Int J Cardiol; 2006 Mar; 108(1):31-5. PubMed ID: 16516696 [TBL] [Abstract][Full Text] [Related]
19. Development of an optimized multimarker strategy for early risk assessment of patients with acute coronary syndromes. Möckel M; Danne O; Müller R; Vollert JO; Müller C; Lueders C; Störk T; Frei U; Koenig W; Dietz R; Jaffe AS Clin Chim Acta; 2008 Jul; 393(2):103-9. PubMed ID: 18423399 [TBL] [Abstract][Full Text] [Related]
20. Distribution and correlates of lipoprotein-associated phospholipase A2 in an elderly cohort: the Cardiovascular Health Study. Furberg CD; Nelson JJ; Solomon C; Cushman M; Jenny NS; Psaty BM J Am Geriatr Soc; 2008 May; 56(5):792-9. PubMed ID: 18363676 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]